2cureX AB (publ) (STO:2CUREX)

Market Cap	57.49M +524.0%
Revenue (ttm)	1.98M -49.7%
Net Income	-26.35M
EPS	-1.50
Shares Out	25.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.08 (3.73%)
Ex-Dividend Date	Jun 27, 2025

Volume	332,453
Average Volume	129,734
Open	2.330
Previous Close	2.250
Day's Range	2.280 - 2.700
52-Week Range	0.514 - 5.520
Beta	2.79
RSI	81.87
Earnings Date	May 21, 2026

About 2cureX AB

2cureX AB (publ) operates as a medical technology company in Europe. The company’s principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient’s tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 14
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: 2CUREX

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.